Cardiac complications of COVID-19 vaccination: now we know more

Area of Science:

• Cardiology
• Immunology
• Public Health

Background:

• Observational studies increasingly detail adverse effects of COVID-19 vaccination, including myocarditis, pericarditis, and arterial hypertension.
• Recent data indicates a 3.2% incidence of significant blood pressure increase post-vaccination, with 0.6% experiencing hypertensive emergencies.

Purpose of the Study:

• To analyze the incidence and potential mechanisms of arterial hypertension following COVID-19 vaccination.
• To compare the risks of myocarditis/pericarditis with the benefits of COVID-19 vaccination in preventing severe COVID-19 outcomes.

Main Methods:

• Review of recent observational studies on COVID-19 vaccine adverse effects.
• Analysis of incidence rates for hypertension and myocarditis/pericarditis.
• Discussion of the proposed biological mechanism involving ACE2 receptors and angiotensin II.

Main Results:

• A 3.2% incidence of significant blood pressure increase and 0.6% incidence of stage III hypertension reported after COVID-19 vaccination.
• Proposed mechanism: SARS-CoV-2 spike protein binding to ACE2 receptors may lead to angiotensin II excess, causing hypertension.
• For individuals aged 12-29, COVID-19 vaccination prevents more hospitalizations, ICU admissions, and deaths than the risk of vaccine-associated myocarditis.

Conclusions:

• While COVID-19 vaccination can cause temporary increases in blood pressure, the benefits, particularly in preventing severe COVID-19, are substantial.
• Post-vaccine myocarditis/pericarditis are generally mild and short-lived with favorable outcomes.
• The overall risk-benefit profile strongly favors COVID-19 vaccination.